Clinical efficacy and prognosis analysis of 18F-FDG PET/CT-guided dose escalation in radiotherapy for esophageal squamous cell carcinoma(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2026年第1期
- Page:
- 9-13
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Clinical efficacy and prognosis analysis of 18F-FDG PET/CT-guided dose escalation in radiotherapy for esophageal squamous cell carcinoma
- Author(s):
- SHI Minghong1; LIU Zhanwei2; ZHU Yang2; XIA Lili2; BAI Gang1; CHENG Gang3; LU Youguo2
- 1. Department of Radiotherapy, Xinhua Hospital of Huainan Xinhua Medical Group, Huainan 232000, China 2. Department of Oncology, Xinhua Hospital of Huainan Xinhua Medical Group, Huainan 232000, China 3. Department of Oncology, the Peoples Hospital of Bozhou, Bozhou 236805, China
- Keywords:
- Keywords: fluorodeoxyglucose positron emission computed tomography esophageal squamous cell carcinoma radiotherapy clinical efficacy prognosis
- PACS:
- R816.5
- DOI:
- DOI:10.3969/j.issn.1005-202X.2026.01.002
- Abstract:
- Abstract: Objective To investigate the clinical efficacy and prognosis of 18F-FDG PET/CT-guided radiotherapy dose escalation in esophageal squamous cell carcinoma (ESCC). Methods The clinical data of 88 patients with ESCC confirmed by pathological diagnosis were retrospectively analyzed. All patients received radiotherapy with dose escalation. The 18F-FDG PET/CT metabolic parameters were collected, including maximum standard uptake value (SUVmax), whole body metabolic tumor volume (MTVwb), and whole body total lesion glycolysis (TLGwb). Kaplan-Meier method, Log-Rank test, and multivariate COX regression analysis were used to analyze the relationships between the above parameters and overall survival (OS). Results The 2-year survival rate was 59.09%, with a median OS of 17.3 (15.2-24.0) months. Univariate analysis showed that clinical stage, tumor diameter, surgical treatment, SUVmax, MTVwb, and TLGwb were associated with OS (P<0.05). Kaplan-Meier survival analysis revealed that the 2-year OS rates were 61.11% for patients with SUVmax≤12.84 versus 32.69% for those with SUVmax > 12.84 (P<0.05), 73.91% for patients with MTVwb≤10.12 versus 47.62% for those with MTVwb>10.12 (P<0.05), and 73.33% for patients with TLGwb≤148.67 versus 44.19% for those with TLGwb>148.67 (P<0.05). Multivariate COX regression analysis identified MTVwb and TLGwb as independent risk factors affecting OS (P<0.05). Conclusion 18F-FDG PET/CT-guided dose escalation in radiotherapy exerts a significant therapeutic effect in ESCC patients. The obtained MTVwb and TLGwb are independent risk factors for the prognosis of ESCC patients, and have favorable predictive efficacy for the prognosis of ESCC patients.
Last Update: 2026-01-26